共 429 条
[11]
Decroisette C(2013)Updated overall survival results from a randomized phase III trial comparing gefitinib with carboplatin-paclitaxel for chemo-naïve non-small cell lung cancer with sensitive EGFR gene mutations (NEJ002) Ann Oncol 24 54-2360
[12]
Schott R(2019)Impact of clinical features on the efficacy of osimertinib therapy in patients with T790M-positive non-small cell lung cancer and acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors J Thorac Dis 11 2350-942
[13]
Le Moulec S(2020)Osimertinib, a third-generation EGFR tyrosine kinase inhibitor: a retrospective multicenter study of its real-world efficacy and safety in advanced/recurrent non-small cell lung carcinoma Thorac Cancer 11 935-43
[14]
Arrondeau J(2021)Clinical implications of germline BCL2L11 deletion polymorphism in pretreated advanced NSCLC patients with osimertinib therapy Lung Cancer 151 39-3571
[15]
Cortot AB(2020)The efficacy and safety of osimertinib in treating nonsmall cell lung cancer: a PRISMA-compliant systematic review and meta-analysis Medicine (baltimore) 99 3567-289
[16]
Gerinière L(2018)Impact of pleural effusion on outcomes of patients receiving osimertinib for NSCLC harboring EGFR T790M Anticancer Res 38 271-957
[17]
Renault A(2016)Cancer treatment and survivorship statistics, 2016 CA Cancer J Clin 66 947-640
[18]
Daniel C(2009)Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma N Engl J Med 361 629-594
[19]
Falchero L(2017)Osimertinib or platinum-pemetrexed in EGFR T790M-positive lung cancer N Engl J Med 376 584-889
[20]
Chouaid C(2008)Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship Mayo Clin Proc 83 880-1622